Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease that commonly occurs in young women. When SLE enters the active phase, most patients will have symptoms of systemic inflammation. Early, mild and atypical cases are increasing day by day. The cause of this disease has not yet been determined. A large number of studies have shown that genetic, endocrine, infection, immune abnormalities and some environmental factors are related to the onset of this disease. Under the interaction of various factors such as genetic factors, environmental factors, estrogen levels, etc., it leads to a decrease in T lymphocytes, a decrease in T suppressor cell function, and excessive proliferation of B cells. A large number of autoantibodies are produced, making the immune system to attack its own tissues, thus causing damage to multiple organs and tissues throughout the body.

Diagnosis of Systemic Lupus Erythematosus

The detection methods for systemic lupus erythematosus are as follows:

• Blood routine. Anemia, decreased red blood cells, leukopenia and thrombocytopenia occur.
• Urinalysis. When the kidneys are involved, abnormal red blood cells, tubular urine, and abnormal increase in urine protein appear.
• Immunological examination. In most patients, gamma globulin and serum IgG levels are elevated. The complement C3, C4, CH50 are decreased, suggesting that systemic erythema may enter the active phase.
• Biochemical examination. The liver function tests of SLE patients are mostly mild to moderate abnormalities, accompanied by elevated alanine aminotransferase and aspartate aminotransferase. Abnormal serum albumin often indicates renal decompensation. Serum urea nitrogen, serum creatinine, serum lipid level, hypersensitive C-reactive protein are all indicators of other tissue damage caused by systemic lupus erythematosus.
• Autoantibody detection. The current clinical routine detection items for SLE-related autoantibodies mainly are ANA, dsDNA, ENA, anti-nucleosome antibodies and anti-phospholipid antibodies. Anti-phospholipid antibodies, including anti-cardiolipin antibody, anti-82-glycoprotein 1 antibody, lupus anticoagulant, etc., contribute to the diagnosis of secondary anti-phospholipid syndrome in systemic lupus erythematosus.
• Imaging examination. Imaging examinations such as CT, ultrasound and MRI are mainly used to discover the damage of systemic lupus erythematosus to various organs.
• Histopathological examination. Skin biopsy and kidney biopsy are also very helpful in diagnosing SLE.

Advantages of Our Products

Immunological autoantibodies usually play a key role in the clinical diagnosis of systemic lupus erythematosus. Creative Biogene's products are mainly for autoantibody examinations, and provide various antibody products to assist the research and diagnosis of SLE. Combined detection of multiple antibodies and dynamic observation can improve the accuracy of laboratory diagnosis of SLE.

Creative Biogene focuses on the field of diagnostic reagents for SLE. We are committed to providing the best products to accelerate the realization of customers' research goals. You can choose us with confidence.

Please contact us for more details.

Reference

1. Thong B, et al. (2016). "Systemic lupus erythematosus diagnosis and management." Rheumatology. kew401.